Both BCL6 peptide inhibitors and small molecule inhibitors have been shown to have potent efficacy against B-cell lymphoma cells [83,84] and BCL6-dependent DLBCL cell lines [85]. This evidence concerns the gene BCL6 and B-cell non-Hodgkin lymphoma.